Nancy Xiao
Partner at Headline Growth @ Headline
San Francisco, United States
Nancy Xiao is a Series B investor at Headline in San Francisco focused on Health Care and Medical. Nancy is a Partner at Headline Growth and heads up the fund's consumer and healthcare practice.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Nancy Xiao invests in
Stages Nancy Xiao invests in
Countries Nancy Xiao invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series B
- $50M–$60M
- Series D
- $110M–$163M
Investment Focus
Industry
- Health Care 3 (43%)
- Medical 2 (29%)
- Artificial Intelligence 2 (29%)
- Credit 1 (14%)
- Family 1 (14%)
Stage
- Series B 2 (29%)
- Series D 2 (29%)
- Seed 1 (14%)
- Series C 1 (14%)
- Venture - Series Unknown 1 (14%)
Country
- United States 3 (43%)
- Indonesia 1 (14%)
- Switzerland 1 (14%)
- United Kingdom 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Scarlet certifies software medical devices. We’re Europe's only Notified Body specialised in software and AI, and have crafted a certification process that is built for software, and is thus significantly more efficient.This is how we deliver on our mission to hasten the world’s transition to accessible healthcare: by enabling manufacturersto release their medical software and AI to those who need it without unnecessary delays.We are designated as a UK Approved Body by the MHRA, and an EU Notified Body by the Dutch Ministry of Health and the European Commission. | $50M / Series B / Oct 12, 2026 | ||
| SWORD Health is a digital musculoskeletal (MSK) therapy provider. The company pairs licensed physical therapists with innovative technology to help people overcome their chronic and post-surgical pain faster and more cost-effectively. We’re on a mission to free two billion people from pain by making it simple for people to recover at home, withoutresorting to imaging, surgeries, or opioids. Since launching in 2015, SWORD Health has worked with insurers, health systems, and employers in Europe, Australia, and the U.S. to give thousands of people access to preventative, chronic, and post-surgical MSK care that gets results. SWORD Health has offices in New York City, Chicago, Salt Lake City, Sydney, and Porto. | $163M / Series D / Nov 22, 2021 | ||
| Maven Clinic operates an on-demand digital care clinic that assists mothers and families during conception, throughout pregnancy, and postpartum. It offers video appointments and private messaging with its proprietary women's and family health practitioner network, as well as a family benefits platform. Maven Clinic offers its services forIVF and egg-freezing tracks, pregnancy, postpartum, partner, adoption, surrogacy, and loss tracks, and career coaching and support, and customized manager training for HR. It serves individuals, employers, and healthcare professionals. It was founded in 2014 by Katherine Ryder and is headquartered in New York City. | $110M / Series D / Aug 17, 2021 | ||
| SWORD Health is a digital musculoskeletal (MSK) therapy provider. The company pairs licensed physical therapists with innovative technology to help people overcome their chronic and post-surgical pain faster and more cost-effectively. We’re on a mission to free two billion people from pain by making it simple for people to recover at home, withoutresorting to imaging, surgeries, or opioids. Since launching in 2015, SWORD Health has worked with insurers, health systems, and employers in Europe, Australia, and the U.S. to give thousands of people access to preventative, chronic, and post-surgical MSK care that gets results. SWORD Health has offices in New York City, Chicago, Salt Lake City, Sydney, and Porto. | $85M / Series C / Jun 30, 2021 | ||
| AKASA is the leading developer of AI-powered automation for the revenue cycle. We deliver comprehensive automation for complex workflows. This helps healthcare providers improve revenue outcomes, achieve greater efficiency, elevate their teams, and allocate resources where they matter most. From prior authorization to claims processing, weprovide innovative and reliable revenue cycle solutions that give providers peace of mind.AKASA applies advanced technology (such as AI and LLMs) to automate revenue cycle tasks that are complex and time-consuming, and were previously un-solvable at scale. Our solutions are built on deep revenue cycle expertise, grounded in the highest standards for data security, and provide measurable results with accuracy, speed, and completeness.We’ve helped healthcare providers decrease A/R days by 13%, increase efficiency by 86%, save 300+ hours of staff time per month, and increase gross yield by $30M. With investors that include Andreessen Horowitz, BOND, Costanoa Ventures, and more, we’ve raised more than $200M to help eliminate the financial complexity of healthcare. We’re rebuilding the healthcare revenue cycle with AI. | $60M / Series B / Mar 23, 2021 | ||
| BukuWarung is a Y-Combinator backed technology company that is building the digital infrastructure for 60 million MSMEs in Indonesia, enabling them to efficiently manage and grow their business, starting with digital bookkeeping, online storefront & payments. BukuWarung's vision is to empower 60 million MSMEs in Indonesia to becomefinancially aware and enable them to manage and grow their business using technology. | Seed / Sep 28, 2020 | ||
| On sensation of running by empowering all to run on clouds. Eleven years after market launch, On delivers industry-disrupting innovation in premium footwear, apparel, and accessories for high-performance running, outdoor, and all-day activities. Fueled by customer-recommendation, On's award-winning CloudTec® innovation, purposeful design andgroundbreaking strides in sportswear's circular economy have attracted a fast-growing global fanbase — inspiring humans to explore, discover and dream on. | Venture - Series Unknown / Nov 25, 2019 |
Co-Investors
About Headline
Headline (formerly e.ventures) is a Venture Capital firm actively on the ground in 7 cities around the world. It invests across geographies, leading rounds at every stage. The firm's Early Stage Funds are based in the US, Europe, Asia, and Brazil, and invest locally. Its San Francisco-based Growth Fund invests globally from Series B and beyond, working in collaboration with their Early Stage Teams. The sizes and locations of these funds make it possible for them to see local trends up close, identify winning founders, and lead rounds at every stage. Sonos, The RealReal, Creditas, Sorare, Pismo, AppFolio, goPuff, Acorns, Farfetch, Segment, Bumble, and Yeahka are among the stars in Headline’s world. Headline was founded in San Francisco, California in 1998.
Headline Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andreas Haug
Founding and General Partner
|
|||
Christian Miele
General Partner
|
|||
Conrad Chu
Partner
|
|||
Jonathan Becker
Partner
|
|||
Jonathan Userovici
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nancy Xiao invest in?
Nancy Xiao invests primarily in Health Care, Medical and Artificial Intelligence startups, most often at Series B and Series D stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Nancy Xiao invest in?
Nancy Xiao typically joins rounds of $50M–$60M at Series B and $110M–$163M at Series D. These are whole funding-round sizes, not Nancy Xiao's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Nancy Xiao took part in.
How do I contact Nancy Xiao?
Public channels for Nancy Xiao include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Nancy Xiao last invest?
The most recent investment recorded for Nancy Xiao closed in Oct 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
